BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17822462)

  • 1. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.
    Roehrborn CG; Nuckolls JG; Wei JT; Steers W;
    BJU Int; 2007 Oct; 100(4):813-9. PubMed ID: 17822462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
    Rosen RC; Wei JT; Althof SE; Seftel AD; Miner M; Perelman MA;
    Urology; 2009 Mar; 73(3):562-6. PubMed ID: 19167031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries.
    Fourcade RO; Théret N; Taïeb C;
    BJU Int; 2008 May; 101(9):1111-8. PubMed ID: 18279447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rosen RC; Fitzpatrick JM;
    BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
    Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
    Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)].
    Rosen R; Altwein J; Boyle P; Kirby RS; Lukacs B; Meuleman E; O'Leary MP; Puppo P; Chris R; Giuliano F
    Prog Urol; 2004 Jun; 14(3):332-44. PubMed ID: 15373175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty.
    Seftel AD; Rosen RC; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2008 Apr; 62(4):614-22. PubMed ID: 18266709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
    Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
    Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study)].
    Horchani A; Binous MY; Ben Hamida A; Sallami S; El Adbi H; Naji A
    Tunis Med; 2007 Aug; 85(8):619-24. PubMed ID: 18254279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.